2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2291 MASS-bridge MM: Bridging serum mass spectrometry, protein electrophoresis, and immunofixation for standardized monoclonal protein assessment

Noemí Puig, MD, Cristina Agullo, MD, PhD2, Mattia D'Agostino, MD3, Sergio Castro, MSc4, María Cortés5, Meletios-Athanasios (Thanos) C. Dimopoulos, MD6, Ka Lung Wu, MD, PhD7, Roman Hajek, MD, PhD8, Angelo Belotti, MD9, Silvia Mangiacavalli, MD10, Esther De Waal, MD11, Enrique Ocio Sr, MD, PhD12, Mark-David Levin, MD, PhD13, Fredrik Schjesvold, MD,PhD14, Francesco Vassallo, MD15, Joan Batista Blade Creixenti Sr, MD16, Hermann Einsele, MD, PhD17, Maria-Victoria Mateos Jr, MD, PhD18, Annemiek Broijl, PhD19, Mario Boccadoro, MD20, Pieter Sonneveld, MD, PhD21, Francesca Gay, MD, PhD22
1 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain
2 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
3 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
4 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
5 Department of Statistics, Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain
6 Korea University, Seoul, Korea, Rep. of South, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
7 ZAS Cadix, Antwerp, Belgium
8 University Hospital Ostrava, Ostrava, Czech Republic
9 ASST Spedali Civili di Brescia, Brescia, Italy
10 IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
11 Medisch Centrum Leeuwarden, Leeuwarden, Netherlands
12 Hospital Universitario Marques de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain
13 Albert Schweitzer hospital, Dordrecht, Netherlands
14 KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway, Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
15 Azienda Sanitaria Santa Croce e Carle, Cuneo, Italy
16 Amyloidosis and Myeloma Unit, Hospital Clínic de Barcelona, IDIBAPS and PETHEMA/GEM, Barcelona, Spain
17 University Hospital Würzburg, Würzburg, Germany
18 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain
19 Erasmus MC Cancer Institute, Rotterdam, Netherlands
20 European Myeloma Network (EMN = Torino), Torino, Italy, University of Torino, Torino, Italy
21 Erasmus MC Cancer Institute, Rotterdam, Netherlands, European Myeloma Network (EMN = Rotterdam), Rotterdam, Netherlands
22 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

Background. Serum protein electrophoresis (SPEP) provides quantitative assessment of monoclonal protein burden, whereas immunofixation (IFE) establishes the presence or absence of residual monoclonal protein but lacks quantitative output and is subject to observer-dependent interpretation. Serum mass spectrometry (MS) combines high analytical sensitivity with quantitative measurement and therefore has the potential to bridge these complementary techniques. We developed and validated a quantitative framework linking EXENTTM MS (The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK) with both SPEP and a standardized serum IFE assay.

Methods. Transplant eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase III IsKia trial (NCT04483739) received Isa-KRd or KRd induction, ASCT, consolidation, and light consolidation.

Serum samples were analyzed centrally in Salamanca using quantitative immunoprecipitation mass spectrometry with anti-IgG/A/M, total κ and total λ beads in the EXENT Analyzer. SPEP was performed according to each participating center's standard laboratory procedures. Serum IFE was performed centrally in Salamanca using the Vitresi® system (Menarini Diagnostics) and classified as positive or negative for monoclonal protein, serving as the qualitative reference method. Detectable EXENT results below the lower limit of quantification (0.015 g/L) were assigned a value of 0.0075 g/L.

Passing–Bablok and Deming regression were used to characterize the quantitative relationship between MS and SPEP. Bidirectional isotype-specific prediction models were developed to estimate SPEP from MS and MS from SPEP, and validated using patient-grouped cross-validation. Agreement between observed and predicted values was assessed by Bland–Altman analysis. IFE positivity was modeled using generalized estimating equation logistic regression with repeated patient-grouped five-fold cross-validation and 1,000 bootstrap replicates. Clinically relevant probability zones (≤20%, 20–80%, and ≥80%) were predefined. Final models were implemented in the MASS-Bridge MM web application. Predictive performance was assessed using the mean absolute error (MAE) and the out-of-sample predictive R².

Results. Following quality control, 485 paired MS-SPEP measurements from 192 patients (384 IgG and 101 IgA) were included.

EXENT demonstrated excellent quantitative agreement with SPEP, accurately predicting SPEP concentrations, with out-of-sample predictive R² values of 0.900 for IgG and 0.808 for IgA, low prediction errors (MAE 3.22 and 4.68 g/L, respectively), and minimal systematic bias. Prediction of EXENT from SPEP was less accurate than the reverse approach, particularly for IgA, with predictive R² values of 0.882 and 0.709 and MAEs of 5.13 and 8.44 g/L for IgG and IgA, respectively.

Beyond quantitative agreement, EXENT accurately predicted IFE status, achieving out-of-sample AUCs of 0.931 for IgG and 0.966 for IgA. Probabilistic modeling identified clinically meaningful probability-based interpretation zones. MS concentrations <0.041 g/L (IgG) and <0.064 g/L (IgA) were associated with a ≤20% probability of IFE positivity, whereas concentrations ≥0.490 g/L and ≥0.448 g/L, respectively, were associated with an ≥80% probability of positivity.

These models have been implemented in the MASS-Bridge MM web application, enabling bidirectional quantitative estimation between EXENT-derived GAM and SPEP, together with individualized probabilities of IFE positivity from a single EXENT measurement. The platform also supports the online incorporation of anonymized datasets from additional institutions, enabling continuous external validation and iterative refinement of the predictive models.

Conclusions. EXENT provides a quantitative bridge between SPEP and standardized serum IFE, combining accurate monoclonal protein quantification with probabilistic prediction of IFE positivity. MASS-Bridge MM translates these models into an intuitive tool, enabling bidirectional quantitative estimation between EXENT and SPEP together with individualized probabilities of IFE positivity. The platform supports continuous external validation and model refinement through incorporation of multicenter data, facilitating standardized interpretation of serum mass spectrometry and future MS-based response assessment in multiple myeloma.

Noemí Puig, MD: BD/Waters - Honoraria; Amgen - Honoraria; Regeneron - Honoraria; Menarini - Honoraria; GSK - Honoraria; Thermo Fisher Scientific - Honoraria; Kite Pharma - Honoraria; Janssen - Honoraria; Takeda - Honoraria; Sanofi - Honoraria; Oncopeptides - Honoraria; Celgene/Bristol Myers Squibb - Honoraria; AbbVie - Honoraria; Pfizer - Honoraria; Amgen - Research Funding; Takeda - Research Funding; Kite Pharma - Research Funding; GSK - Research Funding; Sanofi - Research Funding; Janssen - Research Funding; Oncopeptides - Research Funding; Menarini - Research Funding; Celgene/Bristol Myers Squibb - Research Funding; BD/Waters - Research Funding; Pfizer - Research Funding; Regeneron - Research Funding; Thermo Fisher Scientific - Research Funding; AbbVie - Research Funding; Janssen - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Celgene/Bristol Myers Squibb - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Thermo Fisher Scientific - Consultancy (Includes expert testimony); BD/Waters - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony)